A Study to Evaluate Intact FGF23 Performance in Patients with Tumor-induced Osteomalacia (TIO) and X-linked Hypophosphatemia (XLH)


About this study

The purpose of this study is to establish the clinical performance of the Medfrontier Intact FGF23 immunoassay in patients with tumor induced osteomalacia (TIO) and X-linked hypophosphatemia (XLH).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:  

  • Patients with hypophosphatemia or suspected tumor induced osteomalacia (TIO) or suspected or confirmed X-linked hypophosphatemia (XLH).

Exclusion Criteria: 

  • Patients with iron deficiency and chronic kidney disease as these patients might have elevations of FGF23.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Alicia Algeciras-Schimnich, Ph.D.

Open for enrollment

Contact information:

Stephanie Hafner



More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available